Table 1. Patient characteristics.

Age in years/Sex	No. of Prior Inductions	Pretreatment Karyotype	Presenting WBC count × 103/uL	% BM blasts	Response
45/M	2	46,XY,t(6;11)(q27;q23)/46,XY	2.7	4	PD
71/M	4	46, XY	12.3	84	PD
66/M	3	46,XY,t(9;17;10)(q34;p12;q22)/46,XY	1.3	81	CR
70/M	3	94<4n>,XXYY,+13,+13/46,XY	1.6	8	CRi**
75/F	1*	73-87<4n>, XXXX,-7,-7,t(8;21)(q22;q22)x2,-11,-14,-16, -20	3.6	93	CRi**
50/M	3	48,XX,t(6;11)(q27;q23),+21,+21/46,XX	17.2	90	PD
58/F	2*	46,XX,t(6;9)(p23;q24)/47,sl,+i(13)(q10)/ 47,sl,+mar	19.1	87	PD
51/M	3	47,XY+8/46,XY	0.5	11	PD
65/M	1	46,XY,t(4;12)(q12;p13)/46,XY	4.1	2	CR**
72/M	1*	46,XY,t(4;21)(q33;q22)/46,idem,der(3)t(3;4)(p22;q12) -4, add(8)(p12),+mar /48,XY,+21,+21	1.0	42	PR
49/F	2	46,XX,t(6;11)(q27;q23)/46,XX	6.3	85	PD
68/F	2*	43,XX,add(1)(q32),add(5)(q13),-6,-7, der(8) t(8;21)(p21;q11.2), add(12)(p11.2)13, dic(18;22)(q12;p12),der(19)t(6;19)(q11.2;p13.3) ins(19;?)(p13.3;?),der(19)t(13;19)(q14;q13.3), +20,del(20)(q11.2)x2, -21,+mar1[cp2]/46,XX	2.3	15-20	PD
76/M	1*	44,X,-Y,add(5)(q12),-7,del(8)(q?24),dic(?;12)(?;p11.2), der(16)t(16;17)(p13. 3;q12),-17,add(17)(p11.2),-18,-20, der(21) t(Y;21)(q11.23;p11.2),22,+r,+mar10, +mar11,+mar12/ 44,idem,del(3)(p11.2p21) +mar9, -mar12/46,XY	4.3	72	PD
62/F	1*	46, XX	2.5	35	PD
65/M	2	46,XY,del(11)(q13q23)/46,XY	39.1	8	PD
65M	1	46,XY,t(14;16)(q24;p13.3)/46,XY	24.5	10	PD
60/M	4	46,XY,t(9;22)(q34;q11.2)/46,XY,idem,del(6)(p23)	12.6	14	PD
75/M	5*	46,XY,dup(1)(q21q41)/46,XY	59.1	82	PD
50/M	3	46,XY	2.3	5-7	PD
77/F	2*	46,XX,del(5)(q22q35)/46,XX	1.8	26	PD
42/F	5	46,XX	3.7	23	CRi
81/F	1*	46,XX	3.1	3	PD
77/M	1*	46,XY	7.9	47	PD

PD (Progressive disease)

^*Prior decitabine treatment

^**Patient achieved cytogenetic remission